Table 1. Baseline Characteristics of Study Participants with Data on At Least One Biomarker (Total N=63).
| Category | Variable | Variable Subcategory | rhGH/Rosiglitazone (n = 20) |
Rosiglitazone (n = 15) |
rhGH (n = 13) |
Double Placebo (n = 15) |
|---|---|---|---|---|---|---|
| Demographic | Age, years | 46.0 (41.5,52.0) | 47.0 (45.0,52.0) | 49.0 (47.0,51.0) | 48.0 (42.0,55.0) | |
| Sex | Male | 17 (85.0%) | 13 (86.7%) | 10 (76.9%) | 11 (73.3%) | |
| Race | White | 14 (70.0%) | 11 (73.3%) | 8 (61.5%) | 10 (66.7%) | |
| Black | 5 (25.0%) | 4 (26.7%) | 5 (38.5%) | 6 (33.3%) | ||
| > 1 race | 1 (5.0%) | 0 | 0 | 0 | ||
| Ethnicity | Hispanic | 7 (35.0%) | 8 (53.3%) | 2 (15.4%) | 7 (46.7%) | |
| Non-Hispanic | 13 (65.0%) | 7 (46.7%) | 11 (84.6%) | 8 (53.3%) | ||
| HIV | Antiretro-viral regimen | ≥2 NRTIs + NNRTI | 6 (30.0%) | 6 (40.0%) | 6 (46.1%) | 7 (46.7%) |
| ≥ 2 NRTIs + PI | 10 (50.0%) | 7 (46.7%) | 5 (38.5%) | 7 (46.7%) | ||
| ≥ 3 NRTIs | 2 (10.0%) | 0 | 1 (7.7%) | 0 | ||
| Other | 2 (10.0%) | 2 (13.3%) | 1 (7.7%) | 1 (6.7%) | ||
| Stavudine or zidovudine use | 5 (25.5%) | 5 (33.3%) | 4 (30.8%) | 5 (33.3%) | ||
| Concomitant Medications | Fibrate | 3 (15.0%) | 2 (13.3%) | 2 (15.4%) | 3 (20.0%) | |
| Statin | 7 (35.0%) | 7 (46.7%) | 4 (30.8%) | 3 (20.0%) | ||
| Fish oil | 0 | 1 (6.7%) | 0 | 1 (6.7%) | ||
| Antihypertensive | 6 (30.0%) | 5 (33.3%) | 4 (30.1%) | 5 (33.3%) | ||
| Anthropometric | Height, cm | 171.5 (166.5,176.5) | 173.2 (167.0,177.4) | 173.8 (167.7,179.6) | 172.1 (165.9,175.4) | |
| Weight, kg | 85.1 (75.3,94.1) | 76.7 (71.4,83.0) | 88.5 (82.1,99.2) | 79.4 (71.3,98.8) | ||
| Body mass index, kg/m2 | 29.4 (25.3,31.5) | 26.2 (25.0,28.5) | 29.6 (28.9,32.0) | 28.1 (25.5,33.9) | ||
| Waist circumference, cm | 101.4 (97.0,108.0) | 98.2 (95.2,102.7) | 106.2 (103.3,108.8) | 99.8 (94.2,113.4) | ||
| Hip circumference, cm | 97.8 (95.8,100.0) | 95.0 (92.9,97.2) | 101.5 (99.2,106.9) | 96.7 (92.3,109.3) | ||
| Waist:hip ratio | 1.0 (1.0,1.1) | 1.0 (1.0,1.1) | 1.0 (1.0,1.1) | 1.0 (1.0,1.1) | ||
| Laboratory Values | Fasting insulin, miU/mL | 18.1 (15.2,23.4) | 18.9 (12.2,25.0) | 17.1 (12.2,23.8) | 16.0 (11.9,17.6) | |
| Fasting glucose, mg/dL | 90.5 (83.5,96.5) | 89.0 (81.0,92.0) | 94.0 (90.0,104.0) | 95.0 (89.0,98.0) | ||
| QUICKI | 0.31 (0.30,0.32) | 0.31 (0.30,0.33) | 0.31 (0.29,0.33) | 0.32 (0.30,0.33) | ||
| CD4 count*, cells × 106/L | 556.0 (378.0,755.0) | 737.0 (458.0,792.0) | 495.0 (312.0,682.0) | 604.0 (282.0,718.0) | ||
| HIV RNA < 400** copies/ml | 15 (75.0%) | 11 (78.6%) | 9 (69.2%) | 6 (46.2%) | ||
| VAT, L | 4.4 (2.7,7.3) | 4.8 (4.2,5.6) | 4.4 (3.6,6.4) | 4.9 (3.8,7.4) | ||
| SAT, L | 21.9 (14.2,32.1) | 18.3 (15.9,21.7) | 24.7 (16.5,33.5) | 21.0 (17.1,33.9) | ||
| SI, μU * 10-4 * min-1 * ml-1 | 1.7 (1.1,2.4) | 1.9 (1.4,2.7) | 1.7 (1.1,2.9) | 1.6 (1.5,2.9) | ||
| Insulin AUC, pmol/L*2h | 405.0 (314.0,749.0) | 324.4 (200.4,651.2) | 609.1 (225.4,708.7) | 327.9 (239.8,872.2) | ||
| Glucose AUC, mmol/L*2h | 517.0 (476.8,590.3) | 525.3 (389.4,674.1) | 518.0 (486.5,664.4) | 527.1 (493.3,556.3) | ||
Continuous variables are expressed as median (IQR)
Abbreviations: AUC, area under the curve from 2-hour oral glucose tolerance test; NNRTI, non- nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; QUICKI, quantitative insulin sensitivity check index SAT, subcutaneous adipose tolerance tissue volume; SI, insulin sensitivity by frequently sampled intravenous glucose tolerance test; VAT, visceral adipose tissue volume
*
CD4 count available on n = 18, 13, 11, and 11 in rhGH/rosiglitazone, rosiglitazone, rhGH and double placebo arms respectively
**
HIV RNA data available on n= 20, 14, 13, and 13 in rhGH/rosiglitazone, rosiglitazone, rhGH and double placebo arms respectively